Modulators of multidrug resistance proteins in the management of anticancer and antimicrobial drug resistance and the treatment of inflammatory diseases

Current Topics in Medicinal Chemistry

Volumn 10, Issue 17, 2010, Pages 1732-1756

  Yang, An Kui ^a,b   Zhou, Zhi Wei ^c   Wei, Min Qian ^d   Liu, Jun Ping ^e   Zhou, Shu Feng ^c,f  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c RMIT UNIVERSITY   (Australia)

^d GRIFFITH UNIVERSITY   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cancer; Chemotherapy; Drug resistance; Inflammatory disease; Inhibitor; MRP; Substrate

Indexed keywords

ABACAVIR; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; ATAZANAVIR; BENZBROMARONE; CEFALOTIN; CEFAZOLIN; CEFEPIME; CEFMETAZOLE; CEFOPERAZONE; CEFOTAXIME; CEFSULODIN; CEFTIZOXIME; DARUNAVIR; DIDANOSINE; FOSAMPRENAVIR; INDINAVIR; LEUKOTRIENE; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; NELFINAVIR; PROSTAGLANDIN; RITONAVIR; SAQUINAVIR; TIPRANAVIR; UNINDEXED DRUG; VERLUKAST;

ARTICLE; CELL STRAIN HEK293; DRUG DEVELOPMENT; DRUG STRUCTURE; DRUG TRANSPORT; ENZYME SPECIFICITY; INFLAMMATORY DISEASE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RNA INTERFERENCE; TISSUE DISTRIBUTION; TISSUE SPECIFICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS;

EID: 77958012886     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610792928040     Document Type: Article

References (189)

1. Borst, P.; Elferink, R. O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem., 2002, 71, 537-592.
2. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst., 2000, 92, 1295-1302.
3. Riordan, J. R.; Rommens, J. M.; Kerem, B.; Alon, N.; Rozmahel, R.; Grzelczak, Z.; Zielenski, J.; Lok, S.; Plavsic, N.; Chou, J. L.; Drumm, M. L.; Iannuzzi, M. C.; Collins, F. S.; Tsui, L. C. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science,1989, 245, 1066-1073.
4. Aguilar-Bryan, L.; Nichols, C. G.; Wechsler, S. W.; Clement, J. P. t.; Boyd, A. E., 3rd; Gonzalez, G.; Herrera-Sosa, H.; Nguy, K.; Bryan, J.; Nelson, D. A. Cloning of the -cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science, 1995, 268, 423-426.
5. Yabuuchi, H.; Takayanagi, S.; Yoshinaga, K.; Taniguchi, N.; Aburatani, H.; Ishikawa, T. ABCC13, an unusual truncated ABC transporter, is highly expressed in fetal human liver. Biochem. Biophys. Res. Commun., 2002, 299, 410-417.
6. Annilo, T.; Dean, M. Degeneration of an ATP-binding cassette transporter gene, ABCC13, in different mammalian lineages. Genomics, 2004, 84, 34-46.
7. Zhou, S. F.; Wang, L. L.; Di, Y. M.; Xue, C. C.; Duan, W.; Li, C. G.; Li, Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem., 2008, 15, 1981-2039.
8. Cole, S. P.; Sparks, K. E.; Fraser, K.; Loe, D. W.; Grant, C. E.; Wilson, G. M.; Deeley, R. G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res., 1994, 54, 5902-5910.
9. Zaman, G. J.; Versantvoort, C. H.; Smit, J. J.; Eijdems, E. W.; de Haas, M.; Smith, A. J.; Broxterman, H. J.; Mulder, N. H.; de Vries, E. G.; Baas, F. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res., 1993, 53, 1747-1750.
10. Slapak, C. A.; Fracasso, P. M.; Martell, R. L.; Toppmeyer, D. L.; Lecerf, J. M.; Levy, S. B. Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells. Cancer Res., 1994, 54, 5607-5613.
11. Zaman, G. J.; Flens, M. J.; van Leusden, M. R.; de Haas, M.; Mulder, H. S.; Lankelma, J.; Pinedo, H. M.; Scheper, R. J.; Baas, F.; Broxterman, H. J.; P., B. The human multidrug resistanceassociated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA, 1994, 91, 8822-8826.
12. Morrow, C. S.; Smitherman, P. K.; Diah, S. K.; Schneider, E.; Townsend, A. J. Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. J. Biol. Chem., 1998, 273, 20114-20120.
13. Morrow, C. S.; Peklak-Scott, C.; Bishwokarma, B.; Kute, T. E.; Smitherman, P. K.; Townsend, A. J. Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol. Pharmacol., 2006, 69, 1499-1505.
14. Chu, X. Y.; Kato, Y.; Sugiyama, Y. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. Drug Metab. Dispos., 1999, 27, 440-441.
15. Hooijberg, J. H.; Peters, G. J.; Assaraf, Y. G.; Kathmann, I.; Priest, D. G.; Bunni, M. A.; Veerman, A. J.; Scheffer, G. L.; Kaspers, G. J.; Jansen, G. The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochem. Pharmacol., 2003, 65, 765-771.
16. Hooijberg, J. H.; Broxterman, H. J.; Kool, M.; Assaraf, Y. G.; Peters, G. J.; Noordhuis, P.; Scheper, R. J.; Borst, P.; Pinedo, H. M.; Jansen, G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res., 1999, 59, 2532-2535.
17. Grzywacz, M. J.; Yang, J. M.; Hait, W. N. Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide. Cancer Res., 2003, 63, 2492-2498.
18. Pham, A. N.; Wang, J.; Fang, J.; Gao, X.; Zhang, Y.; Blower, P. E.; Sadee, W.; Huang, Y. Pharmacogenomics approach reveals MRP1 (ABCC1)-mediated resistance to geldanamycins. Pharm. Res., 2009, 26, 936-945.
19. Czyzewski, K.; Styczynski, J. Imatinib is a substrate for various multidrug resistance proteins. Neoplasma, 2009, 56, 202-207.
20. Paumi, C. M.; Ledford, B. G.; Smitherman, P. K.; Townsend, A. J.; Morrow, C. S. Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. J. Biol. Chem., 2001, 276, 7952-7956.
21. Barnouin, K.; Leier, I.; Jedlitschky, G.; Pourtier-Manzanedo, A.; Konig, J.; Lehmann, W. D.; Keppler, D. Multidrug resistance proteinmediated transport of chlorambucil and melphalan conjugated to glutathione. Br. J. Cancer, 1998, 77, 201-209.
22. Priebe, W.; Krawczyk, M.; Kuo, M. T.; Yamane, Y.; Savaraj, N.; Ishikawa, T. Doxorubicinand daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochem. Biophys. Res. Commun., 1998, 247, 859-863.
23. + chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia, 2009, 23, 1999-2006.
24. Cui, Y.; Konig, J.; Buchholz, J. K.; Spring, H.; Leier, I.; Keppler, D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol., 1999, 55, 929-937.
25. Vlaming, M. L.; Pala, Z.; van Esch, A.; Wagenaar, E.; van Tellingen, O.; de Waart, D. R.; Oude Elferink, R. P.; van de Wetering, K.; Schinkel, A. H. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin. Cancer Res., 2008, 14, 8152-8160.
26. Marchetti, S.; Oostendorp, R. L.; Pluim, D.; van Eijndhoven, M.; van Tellingen, O.; Schinkel, A. H.; Versace, R.; Beijnen, J. H.; Mazzanti, R.; Schellens, J. H. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2. Mol. Cancer Ther., 2007, 6, 3307-3313.
27. Kool, M.; van der Linden, M.; de Haas, M.; Scheffer, G. L.; de Vree, J. M.; Smith, A. J.; Jansen, G.; Peters, G. J.; Ponne, N.; Scheper, R. J.; Elferink, R. P.; Baas, F.; Borst, P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA, 1999, 96, 6914-6919.
28. Zelcer, N.; Saeki, T.; Reid, G.; Beijnen, J. H.; Borst, P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J. Biol. Chem., 2001, 276, 46400-46407.
29. Chen, Z. S.; Lee, K.; Kruh, G. D. Transport of cyclic nucleotides and estradiol 17-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J. Biol. Chem., 2001, 276, 33747-33754.
30. Wijnholds, J.; Mol, C. A.; van Deemter, L.; de Haas, M.; Scheffer, G. L.; Baas, F.; Beijnen, J. H.; Scheper, R. J.; Hatse, S.; De Clercq, E.; Balzarini, J.; Borst, P. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. USA, 2000, 97, 7476-7481.
31. McAleer, M. A.; Breen, M. A.; White, N. L.; Matthews, N. pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J. Biol. Chem., 1999, 274, 23541-23548.
32. Hagmann, W.; Jesnowski, R.; Faissner, R.; Guo, C.; Lohr, J. M. ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology, 2009, 9, 136-144.
33. Jedlitschky, G.; Burchell, B.; Keppler, D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem., 2000, 275, 30069-30074.
34. Liu, Y. H.; Di, Y. M.; Zhou, Z. W.; Mo, S. L.; Zhou, S. F. Multidrug resistance associated proteins and implications in drug development. Clin. Exp. Pharmacol. Physiol., 2010, 37, 115-120.
35. Belinsky, M. G.; Chen, Z. S.; Shchaveleva, I.; Zeng, H.; Kruh, G. D. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res., 2002, 62, 6172-6177.
36. Chen, Z. S.; Hopper-Borge, E.; Belinsky, M. G.; Shchaveleva, I.; Kotova, E.; Kruh, G. D. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol. Pharmacol., 2003, 63, 351-358.
37. Hopper-Borge, E.; Chen, Z. S.; Shchaveleva, I.; Belinsky, M. G.; Kruh, G. D. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res., 2004, 64, 4927-4930.
38. Hopper-Borge, E.; Xu, X.; Shen, T.; Shi, Z.; Chen, Z. S.; Kruh, G. D. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res., 2009, 69, 178-184.
39. Bessho, Y.; Oguri, T.; Ozasa, H.; Uemura, T.; Sakamoto, H.; Miyazaki, M.; Maeno, K.; Sato, S.; Ueda, R. ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer. Oncol. Rep., 2009, 21, 263-268.
40. Guo, Y.; Kotova, E.; Chen, Z. S.; Lee, K.; Hopper-Borge, E.; Belinsky, M. G.; Kruh, G. D. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'zsphosphonylmethoxyethyl)adenine. J. Biol. Chem., 2003, 278, 29509-29514.
41. Oguri, T.; Bessho, Y.; Achiwa, H.; Ozasa, H.; Maeno, K.; Maeda, H.; Sato, S.; Ueda, R. MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol. Cancer Ther., 2007, 6, 122-127.
42. Ono, N.; Van der Heijden, I.; Scheffer, G. L.; Van de Wetering, K.; Van Deemter, E.; De Haas, M.; Boerke, A.; Gadella, B. M.; De Rooij, D. G.; Neefjes, J. J.; Groothuis, T. A.; Oomen, L.; Brocks, L.; Ishikawa, T.; Borst, P. Multidrug resistanceassociated protein 9 (ABCC12) is present in mouse and boar sperm. Biochem. J., 2007, 406, 31-40.
43. Sarkadi, B.; Homolya, L.; Szakacs, G.; Varadi, A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev., 2006, 86, 1179-1236.
44. Wakabayashi, K.; Tamura, A.; Saito, H.; Onishi, Y.; Ishikawa, T. Human ABC transporter ABCG2 in xenobiotic protection and redox biology. Drug Metab. Rev., 2006, 38, 371-391.
45. Tian, Q.; Zhang, J.; Chan, S. Y.; Tan, T. M.; Duan, W.; Huang, M.; Zhu, Y. Z.; Chan, E.; Yu, Q.; Nie, Y. Q.; Ho, P. C.; Li, Q.; Ng, K. Y.; Yang, H. Y.; Wei, H.; Bian, J. S.; Zhou, S. F. Topotecan is a substrate for multidrug resistance associated protein 4. Curr. Drug Metab., 2006, 7, 105-118.
46. Sharom, F. J. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics, 2008, 9, 105-127.
47. Noguchi, K.; Katayama, K.; Mitsuhashi, J.; Sugimoto, Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv. Drug Deliv. Rev., 2009, 61, 26-33.
48. Sakamoto, H.; Hara, H.; Hirano, K.; Adachi, T. Enhancement of glucuronosyl etoposide transport by glutathione in multidrug resistance-associated protein-overexpressing cells. Cancer Lett., 1999, 135, 113-119.
49. Leier, I.; Jedlitschky, G.; Buchholz, U.; Cole, S. P.; Deeley, R. G.; Keppler, D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem., 1994, 269, 27807-27810.
50. Jedlitschky, G.; Leier, I.; Buchholz, U.; Center, M.; Keppler, D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res., 1994, 54, 4833-4836.
51. Muller, M.; Meijer, C.; Zaman, G. J.; Borst, P.; Scheper, R. J.; Mulder, N. H.; de Vries, E. G.; Jansen, P. L. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. USA, 1994, 91, 13033-13037.
52. Loe, D. W.; Deeley, R. G.; Cole, S. P. Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer, 1996, 32A, 945-957.
53. Jedlitschky, G.; Leier, I.; Buchholz, U.; Barnouin, K.; Kurz, G.; Keppler, D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res., 1996, 56, 988-994.
54. Lautier, D.; Canitrot, Y.; Deeley, R. G.; Cole, S. P. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem. Pharmacol., 1996, 52, 967-977.
55. Mickisch, G. H.; Merlino, G. T.; Galski, H.; Gottesman, M. M.; Pastan, I. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc. Natl. Acad. Sci. USA, 1991, 88, 547-551.
56. Grant, C. E.; Valdimarsson, G.; Hipfner, D. R.; Almquist, K. C.; Cole, S. P.; Deeley, R. G. Overexpression of multidrug resistanceassociated protein (MRP) increases resistance to natural product drugs. Cancer Res., 1994, 54, 357-361.
57. Warnke, D.; Barreto, J.; Temesgen, Z. Antiretroviral drugs. J. Clin. Pharmacol., 2007, 47, 1570-1579.
58. Dueweke, T. J.; Poppe, S. M.; Romero, D. L.; Swaney, S. M.; So, A. G.; Downey, K. M.; Althaus, I. W.; Reusser, F.; Busso, M.; Resnick, L.; Mayers, D. L.; Lane, J.; Aristoff, P. A.; Thomas, A. C.; Tarpley, W. G. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother., 1993, 37, 1127-1131.
59. Fisher, E. J.; Chaloner, K.; Cohn, D. L.; Grant, L. B.; Alston, B.; Brosgart, C. L.; Schmetter, B.; El-Sadr, W. M.; Sampson, J. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. Aids, 2001, 15, 1695-1700.
60. Williams, G. C.; Liu, A.; Knipp, G.; Sinko, P. J. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob. Agents Chemother., 2002, 46, 3456-3462.
61. Srinivas, R. V.; Middlemas, D.; Flynn, P.; Fridland, A. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob. Agents Chemother., 1998, 42, 3157-3162.
62. Huisman, M. T.; Smit, J. W.; Crommentuyn, K. M.; Zelcer, N.; Wiltshire, H. R.; Beijnen, J. H.; Schinkel, A. H. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. Aids, 2002, 16, 2295-2301.
63. Agarwal, S.; Pal, D.; Mitra, A. K. Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int. J. Pharm., 2007, 339, 139-147.
64. Lee, K.; Klein-Szanto, A. J.; Kruh, G. D. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J. Natl. Cancer Inst., 2000, 92, 1934-1940.
65. Sampath, J.; Adachi, M.; Hatse, S.; Naesens, L.; Balzarini, J.; Flatley, R. M.; Matherly, L. H.; Schuetz, J. D. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci., 2002, 4, E14.
66. Imaoka, T.; Kusuhara, H.; Adachi, M.; Schuetz, J. D.; Takeuchi, K.; Sugiyama, Y. Functional involvement of multidrug resistance associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol. Pharmacol., 2007, 71, 619-627.
67. Reid, G.; Wielinga, P.; Zelcer, N.; De Haas, M.; Van Deemter, L.; Wijnholds, J.; Balzarini, J.; Borst, P. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol. Pharmacol., 2003, 63, 1094-1103.
68. Schuetz, J. D.; Connelly, M. C.; Sun, D. X.; Paibir, S. G.; Flynn, P. M.; Srinivas, R. V.; Kumar, A.; Fridland, A. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med., 1999, 5, 1048-1051.
69. Adachi, M.; Sampath, J.; Lan, L. B.; Sun, D.; Hargrove, P.; Flatley, R.; Tatum, A.; Edwards, M. Z.; Wezeman, M.; Matherly, L.; Drake, R.; Schuetz, J. Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J. Biol. Chem., 2002, 277, 38998-39004.
70. Mazzei, T.; Dentico, P. The pharmacokinetics of oral cephalosporins. Clin. Microbiol. Infect., 2000, 6(Suppl 3), 53-54.
71. Ci, L.; Kusuhara, H.; Adachi, M.; Schuetz, J. D.; Takeuchi, K.; Sugiyama, Y. Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney. Mol. Pharmacol., 2007, 71, 1591-1597.
72. Xiong, H.; Turner, K. C.; Ward, E. S.; Jansen, P. L. M.; Brouwer, K. L. R. Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistanceassociated protein 2-deficient TR-rats. J. Pharmacol. Exp. Ther., 2000, 295, 512-518.
73. Xiong, H.; Suzuki, H.; Sugiyama, Y.; Meier, P. J.; Pollack, G. M.; Brouwer, K. L. Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment. Drug Metab. Dispos., 2002, 30, 962-969.
74. Suzuki, H.; Sugiyama, Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev., 2002, 54, 1311-1331.
75. Schuster, V. L. Prostaglandin transport. Prostaglandins Other Lipid Mediat., 2002, 68-69, 633-647.
76. Brash, A. R. Arachidonic acid as a bioactive molecule. J. Clin. Invest., 2001, 107, 1339-1345.
77. Akimaru, K.; Kuo, M. T.; Furuta, K.; Suzuki, M.; Noyori, R.; Ishikawa, T. Induction of MRP/GS-X pump and cellular resistance to anticancer prostaglandins. Cytotechnology, 1996, 19, 221-227.
78. Ishikawa, T.; Akimaru, K.; Nakanishi, M.; Tomokiyo, K.; Furuta, K.; Suzuki, M.; Noyori, R. Anti-cancer-prostaglandin induced cell-cycle arrest and its modulation by an inhibitor of the ATP-dependent glutathione S-conjugate export pump (GS-X pump). Biochem. J., 1998, 336 (Pt 3), 569-576.
79. Evers, R.; Cnubben, N. H.; Wijnholds, J.; van Deemter, L.; van Bladeren, P. J.; Borst, P. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett., 1997, 419, 112-116.
80. Evers, R.; Kool, M.; van Deemter, L.; Janssen, H.; Calafat, J.; Oomen, L. C.; Paulusma, C. C.; Oude Elferink, R. P.; Baas, F.; Schinkel, A. H.; Borst, P. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest., 1998, 101, 1310-1319.
81. Wijnholds, J.; Evers, R.; van Leusden, M. R.; Mol, C. A.; Zaman, G. J.; Mayer, U.; Beijnen, J. H.; van der Valk, M.; Krimpenfort, P.; Borst, P. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat. Med., 1997, 3, 1275-1279.
82. Zeng, H.; Liu, G.; Rea, P. A.; Kruh, G. D. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res., 2000, 60, 4779-4784.
83. Chu, X. Y.; Huskey, S. E.; Braun, M. P.; Sarkadi, B.; Evans, D. C.; Evers, R. Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3. J. Pharmacol. Exp. Ther., 2004, 309, 156-164.
84. Kruh, G. D.; Guo, Y.; Hopper-Borge, E.; Belinsky, M. G.; Chen, Z. S. ABCC10, ABCC11, and ABCC12. Pflugers Arch., 2007, 453, 675-684.
85. Bortfeld, M.; Rius, M.; Konig, J.; Herold-Mende, C.; Nies, A. T.; Keppler, D. Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience, 2006, 137, 1247-1257.
86. Chen, Z. S.; Guo, Y.; Belinsky, M. G.; Kotova, E.; Kruh, G. D. Transport of bile acids, sulfated steroids, estradiol 17 -D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol. Pharmacol., 2005, 67, 545-557.
87. Loe, D. W.; Oleschuk, C. J.; Deeley, R. G.; Cole, S. P. Structure activity studies of verapamil analogs that modulate transport of leukotriene C4 and reduced glutathione by multidrug resistance protein MRP1. Biochem. Biophys. Res. Commun., 2000, 275, 795-803.
88. Deeley, R. G.; Westlake, C.; Cole, S. P. Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev., 2006, 86, 849-899.
89. Qian, Y. M.; Song, W. C.; Cui, H.; Cole, S. P.; Deeley, R. G. Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1. J. Biol. Chem., 2001, 276, 6404-6411.
90. Haimeur, A.; Conseil, G.; Deeley, R. G.; Cole, S. P. Mutations of charged amino acids in or near the transmembrane helices of the second membrane spanning domain differentially affect the substrate specificity and transport activity of the multidrug resistance protein MRP1 (ABCC1). Mol. Pharmacol., 2004, 65, 1375-1385.
91. Haimeur, A.; Deeley, R. G.; Cole, S. P. Charged amino acids in the sixth transmembrane helix of multidrug resistance protein 1 (MRP1/ABCC1) are critical determinants of transport activity. J. Biol. Chem., 2002, 277, 41326-41333.
92. Wu, P.; Oleschuk, C. J.; Mao, Q.; Keller, B. O.; Deeley, R. G.; Cole, S. P. Analysis of human multidrug resistance protein 1 (ABCC1) by matrix-assisted laser desorption ionization/time of flight mass spectrometry: toward identification of leukotriene C4 binding sites. Mol. Pharmacol., 2005, 68, 1455-1465.
93. Noguchi, T.; Ren, X. Q.; Aoki, S.; Igarashi, Y.; Che, X. F.; Nakajima, Y.; Takahashi, H.; Mitsuo, R.; Tsujikawa, K.; Sumizawa, T.; Haraguchi, M.; Kobayashi, M.; Goto, S.; Kanehisa, M.; Aikou, T.; Akiyama, S.; Furukawa, T. MRP1 mutated in the L0 region transports SN-38 but not leukotriene C4 or estradiol-17 (-D-glucuronate). Biochem. Pharmacol., 2005, 70, 1056-1065.
94. Ren, X. Q.; Furukawa, T.; Aoki, S.; Sumizawa, T.; Haraguchi, M.; Nakajima, Y.; Ikeda, R.; Kobayashi, M.; Akiyama, S. A positively charged amino acid proximal to the C-terminus of TM17 of MRP1 is indispensable for GSH-dependent binding of substrates and for transport of LTC4. Biochemistry, 2002, 41, 14132-14140.
95. Campbell, J. D.; Koike, K.; Moreau, C.; Sansom, M. S.; Deeley, R. G.; Cole, S. P. Molecular modeling correctly predicts the functional importance of Phe594 in transmembrane helix 11 of the multidrug resistance protein, MRP1 (ABCC1). J. Biol. Chem., 2004, 279, 463-468.
96. Robbiani, D. F.; Finch, R. A.; Jager, D.; Muller, W. A.; Sartorelli, A. C.; Randolph, G. J. The leukotriene C4 transporter MRP1 regulates CCL19 (MIP-3, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell, 2000, 103, 757-768.
97. Russel, F. G.; Koenderink, J. B.; Masereeuw, R. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol. Sci., 2008, 29, 200-207.
98. Chen, Z. S.; Lee, K.; Walther, S.; Raftogianis, R. B.; Kuwano, M.; Zeng, H.; Kruh, G. D. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res., 2002, 62, 3144-3150.
99. Bakos, E.; Evers, R.; Calenda, G.; Tusnady, G. E.; Szakacs, G.; Varadi, A.; Sarkadi, B. Characterization of the amino-terminal regions in the human multidrug resistance protein (MRP1). J. Cell Sci., 2000, 113 (Pt 24), 4451-4461.
100. Bera, T. K.; Iavarone, C.; Kumar, V.; Lee, S.; Lee, B.; Pastan, I. MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc. Natl. Acad. Sci. USA, 2002, 99, 6997-7002.
101. Draper, M. P.; Martell, R. L.; Levy, S. B. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br. J. Cancer, 1997, 75, 810-815.
102. Bakos, E.; Evers, R.; Sinko, E.; Varadi, A.; Borst, P.; Sarkadi, B. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol., 2000, 57, 760-768.
103. Stamp, L. K.; O'Donnell, J. L.; Chapman, P. T. Emerging therapies in the long-term management of hyperuricaemia and gout. Intern. Med. J., 2007, 37, 258-266.
104. Evers, R.; de Haas, M.; Sparidans, R.; Beijnen, J.; Wielinga, P. R.; Lankelma, J.; Borst, P. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br. J. Cancer, 2000, 83, 375-383.
105. Jones, T. R.; Zamboni, R.; Belley, M.; Champion, E.; Charette, L.; Ford-Hutchinson, A. W.; Frenette, R.; Gauthier, J. Y.; Leger, S.; Masson, P.; McFarlane, C. S.; Piechuta, H.; Rokach, J.; Williams, H.; Young, R. N.; de Haven, R. N.; Pong, S. S. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can. J. Physiol. Pharmacol., 1989, 67, 17-28.
106. Gekeler, V.; Ise, W.; Sanders, K. H.; Ulrich, W. R.; Beck, J. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem. Biophys. Res. Commun., 1995, 208, 345-352.
107. Leier, I.; Jedlitschky, G.; Buchholz, U.; Center, M.; Cole, S. P.; Deeley, R. G.; Keppler, D. ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem. J., 1996, 314 (Pt 2), 433-437.
108. Tian, Q.; Zhang, J.; Chan, E.; Duan, W.; Zhou, S. F. Multidrug resistance proteins (MRPs) and implication in drug development. Drug Dev. Res., 2005, 51, 1-18.
109. Tian, Q.; Zhang, J.; Tan, T. M.; Chan, E.; Duan, W.; Chan, S. Y.; Boelsterli, U. A.; Ho, P. C.; Yang, H.; Bian, J. S.; Huang, M.; Zhu, Y. Z.; Xiong, W.; Li, X.; Zhou, S. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm. Res., 2005, 22, 1837-1853.
110. Nakano, R.; Oka, M.; Nakamura, T.; Fukuda, M.; Kawabata, S.; Terashi, K.; Tsukamoto, K.; Noguchi, Y.; Soda, H.; Kohno, S. A leukotriene receptor antagonist, ONO-1078, modulates drug sensitivity and leukotriene C4 efflux in lung cancer cells expressing multidrug resistance protein. Biochem. Biophys. Res. Commun., 1998, 251, 307-312.
111. Duffy, C. P.; Elliott, C. J.; O'Connor, R. A.; Heenan, M. M.; Coyle, S.; Cleary, I. M.; Kavanagh, K.; Verhaegen, S.; O'Loughlin, C. M.; NicAmhlaoibh, R.; Clynes, M. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur. J. Cancer, 1998, 34, 1250-1259.
112. Mano, Y.; Usui, T.; Kamimura, H. Contribution of UDPglucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur. J. Clin. Pharmacol., 2007, 63, 289-296.
113. Kuehl, G. E.; Lampe, J. W.; Potter, J. D.; Bigler, J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab. Dispos., 2005, 33, 1027-1035.
114. Barrand, M. A.; Rhodes, T.; Center, M. S.; Twentyman, P. R. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur. J. Cancer, 1993, 29A, 408-415.
115. Hooijberg, J. H.; Broxterman, H. J.; Heijn, M.; Fles, D. L.; Lankelma, J.; Pinedo, H. M. Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. FEBS Lett., 1997, 413, 344-348.
116. Versantvoort, C. H.; Broxterman, H. J.; Lankelma, J.; Feller, N.; Pinedo, H. M. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem. Pharmacol., 1994, 48, 1129-1136.
117. Nguyen, H.; Zhang, S.; Morris, M. E. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J. Pharm. Sci., 2003, 92, 250-257.
118. Hooijberg, J. H.; Broxterman, H. J.; Scheffer, G. L.; Vrasdonk, C.; Heijn, M.; de Jong, M. C.; Scheper, R. J.; Lankelma, J.; Pinedo, H. M. Potent interaction of flavopiridol with MRP1. Br. J. Cancer., 1999, 81, 269-276.
119. Marbeuf-Gueye, C.; Salerno, M.; Quidu, P.; Garnier-Suillerot, A. Inhibition of the P-glycoproteinand multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P. Eur. J. Pharmacol., 2000, 391, 207-216.
120. Aoki, S.; Chen, Z. S.; Higasiyama, K.; Setiawan, A.; Akiyama, S.; Kobayashi, M. Reversing effect of agosterol A, a spongean sterol acetate, on multidrug resistance in human carcinoma cells. Jpn. J. Cancer Res., 2001, 92, 886-895.
121. Bichat, F.; Solis-Recendez, G.; Poullain, M. G.; Poupon, M. F.; Khayat, D.; Bastian, G. S9788 modulation of P-glycoprotein- and multidrug-related protein-mediated multidrug resistance by Servier 9788 in doxorubicin-resistant MCF7 cells. Biochem. Pharmacol., 1998, 56, 497-502.
122. Germann, U. A.; Ford, P. J.; Shlyakhter, D.; Mason, V. S.; Harding, M. W. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs, 1997, 8, 141-155.
123. Minderman, H.; O'Loughlin, K. L.; Pendyala, L.; Baer, M. R. VX710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin. Cancer Res., 2004, 10, 1826-1834.
124. Bandi, N.; Kompella, U. B. Budesonide reduces multidrug resistance associated protein 1 expression in an airway epithelial cell line (Calu- 1). Eur. J. Pharmacol., 2002, 437, 9-17.
125. Payen, L.; Delugin, L.; Courtois, A.; Trinquart, Y.; Guillouzo, A.; Fardel, O. Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Biochem. Biophys. Res. Commun., 1999, 258, 513-518.
126. Sun, M.; Xu, X.; Lu, Q.; Pan, Q.; Hu, X. Schisandrin B: a dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1. Cancer Lett., 2007, 246, 300-307.
127. Naito, S.; Koike, K.; Ono, M.; Machida, T.; Tasaka, S.; Kiue, A.; Koga, H.; Kumazawa, J. Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1- and MRP-mediated multidrug resistance. Oncol. Res., 1998, 10, 123-132.
128. Qiangrong, P.; Wang, T.; Lu, Q.; Hu, X. Schisandrin B-a novel inhibitor of P-glycoprotein. Biochem. Biophys. Res. Commun., 2005, 335, 406-411.
129. Li, L.; Pan, Q.; Sun, M.; Lu, Q.; Hu, X. Dibenzocyclooctadiene lignans: a class of novel inhibitors of multidrug resistance-associated protein 1. Life Sci., 2007, 80, 741-748.
130. Li, L.; Lu, Q.; Shen, Y.; Hu, X. Schisandrin B enhances doxorubicininduced apoptosis of cancer cells but not normal cells. Biochem. Pharmacol., 2006, 71, 584-595.
131. Leslie, E. M.; Mao, Q.; Oleschuk, C. J.; Deeley, R. G.; Cole, S. P. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids. Mol. Pharmacol., 2001, 59, 1171-1180.
132. Bobrowska-Hagerstrand, M.; Wrobel, A.; Mrowczynska, L.; Soderstrom, T.; Shirataki, Y.; Motohashi, N.; Molnar, J.; Michalak, K.; Hagerstrand, H. Flavonoids as inhibitors of MRP1-like efflux activity in human erythrocytes. A structure-activity relationship study. Oncol. Res., 2003, 13, 463-469.
133. Loe, D. W.; Deeley, R. G.; Cole, S. P. Characterization of vincristine transport by the Mr 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res., 1998, 58, 5130-5136.
134. Bobrowska-Hagerstrand, M.; Lillas, M.; Mrowczynska, L.; Wrobel, A.; Shirataki, Y.; Motohashi, N.; Hagerstrand, H. Resveratrol oligomers are potent MRP1 transport inhibitors. Anticancer Res., 2006, 26, 2081-2084.
135. Weiss, J.; Theile, D.; Ketabi-Kiyanvash, N.; Lindenmaier, H.; Haefeli, W. E. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab. Dispos., 2007, 35, 340-344.
136. Pan, G.; Giri, N.; Elmquist, W. F. Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab. Dispos., 2007, 35, 1165-1173.
137. Burg, D.; Wielinga, P.; Zelcer, N.; Saeki, T.; Mulder, G. J.; Borst, P. Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs. Mol. Pharmacol., 2002, 62, 1160-1166.
138. O'Brien, S. J.; Menotti-Raymond, M.; Murphy, W. J.; Nash, W. G.; Wienberg, J.; Stanyon, R.; Copeland, N. G.; Jenkins, N. A.; Womack, J. E.; Marshall Graves, J. A. The promise of comparative genomics in mammals. Science, 1999, 286, 479-481.
139. Payen, L.; Delugin, L.; Courtois, A.; Trinquart, Y.; Guillouzo, A.; Fardel, O. The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells. Br. J. Pharmacol., 2001, 132, 778-784.
140. Sauna, Z. E.; Peng, X. H.; Nandigama, K.; Tekle, S.; Ambudkar, S. V. The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). Mol. Pharmacol., 2004, 65, 675-684.
141. Norman, B. H.; Dantzig, A. H.; Kroin, J. S.; Law, K. L.; Tabas, L. B.; Shepard, R. L.; Palkowitz, A. D.; Hauser, K. L.; Winter, M. A.; Sluka, J. P.; Starling, J. J. Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146. Bioorg. Med. Chem. Lett., 1999, 9, 3381-3386.
142. Norman, B. H.; Lander, P. A.; Gruber, J. M.; Kroin, J. S.; Cohen, J. D.; Jungheim, L. N.; Starling, J. J.; Law, K. L.; Self, T. D.; Tabas, L. B.; Williams, D. C.; Paul, D. C.; Dantzig, A. H. Cyclohexyllinked tricyclic isoxazoles are potent and selective modulators of the multidrug resistance protein (MRP1). Bioorg. Med. Chem. Lett., 2005, 15, 5526-5530.
143. Norman, B. H.; Gruber, J. M.; Hollinshead, S. P.; Wilson, J. W.; Starling, J. J.; Law, K. L.; Self, T. D.; Tabas, L. B.; Williams, D. C.; Paul, D. C.; Wagner, M. M.; Dantzig, A. H. Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1). Bioorg. Med. Chem. Lett., 2002, 12, 883-886.
144. 125I]LY475776. Evidence of a major binding site in the COOH-proximal membrane spanning domain. J. Biol. Chem., 2002, 277, 28690-28699.
145. 35S]glutathione. J. Biol. Chem., 2002, 277, 35225-35231.
146. Ren, X. Q.; Furukawa, T.; Aoki, S.; Nakajima, T.; Sumizawa, T.; Haraguchi, M.; Chen, Z. S.; Kobayashi, M.; Akiyama, S. Glutathione-dependent binding of a photoaffinity analog of agosterol A to the C-terminal half of human multidrug resistance protein. J. Biol. Chem., 2001, 276, 23197-23206.
147. Loe, D. W.; Almquist, K. C.; Cole, S. P.; Deeley, R. G. ATPdependent 17 -estradiol 17-(-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J. Biol. Chem., 1996, 271, 9683-9689.
148. Wang, S.; Wan, N. C.; Harrison, J.; Miller, W.; Chuckowree, I.; Sohal, S.; Hancox, T. C.; Baker, S.; Folkes, A.; Wilson, F.; Thompson, D.; Cocks, S.; Farmer, H.; Boyce, A.; Freathy, C.; Broadbridge, J.; Scott, J.; Depledge, P.; Faint, R.; Mistry, P.; Charlton, P. Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance. J. Med. Chem., 2004, 47, 1339-1350.
149. van Zanden, J. J.; Geraets, L.; Wortelboer, H. M.; van Bladeren, P. J.; Rietjens, I. M.; Cnubben, N. H. Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells. Biochem. Pharmacol., 2004, 67, 1607-1617.
150. Stewart, A. J.; Canitrot, Y.; Baracchini, E.; Dean, N. M.; Deeley, R. G.; Cole, S. P. Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem. Pharmacol., 1996, 51, 461-469.
151. Niewiarowski, W.; Gendaszewska, E.; Rebowski, G.; Wojcik, M.; Mikolajczyk, B.; Goss, W.; Soszynski, M.; Bartosz, G. Multidrug resistance-associated protein-reduction of expression in human leukaemia cells by antisense phosphorothioate olignucleotides. Acta Biochim. Pol., 2000, 47, 1183-1188.
152. Peaston, A. E.; Gardaneh, M.; Franco, A. V.; Hocker, J. E.; Murphy, K. M.; Farnsworth, M. L.; Catchpoole, D. R.; Haber, M.; Norris, M. D.; Lock, R. B.; Marshall, G. M. MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells. Br. J. Cancer, 2001, 85, 1564-1571.
153. Kuss, B. J.; Corbo, M.; Lau, W. M.; Fennell, D. A.; Dean, N. M.; Cotter, F. E. In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: a potential role in neuroblastoma therapy. Int. J. Cancer, 2002, 98, 128-133.
154. Bodo, A.; Bakos, E.; Szeri, F.; Varadi, A.; Sarkadi, B. Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J. Biol. Chem., 2003, 278, 23529-23537.
155. Zelcer, N.; Huisman, M. T.; Reid, G.; Wielinga, P.; Breedveld, P.; Kuil, A.; Knipscheer, P.; Schellens, J. H.; Schinkel, A. H.; Borst, P. Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J. Biol. Chem., 2003, 278, 23538-23544.
156. Gibbs, J. P.; Adeyeye, M. C.; Yang, Z.; Shen, D. D. Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport. Epilepsy Res., 2004, 58, 53-66.
157. Gerk, P. M.; Li, W.; Vore, M. Estradiol 3-glucuronide is transported by the multidrug resistance-associated protein 2 but does not activate the allosteric site bound by estradiol 17-glucuronide. Drug Metab. Dispos., 2004, 32, 1139-1145.
158. Koike, K.; Kawabe, T.; Tanaka, T.; Toh, S.; Uchiumi, T.; Wada, M.; Akiyama, S.; Ono, M.; Kuwano, M. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res., 1997, 57, 5475-5479.
159. Akita, H.; Suzuki, H.; Hirohashi, T.; Takikawa, H.; Sugiyama, Y. Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm. Res., 2002, 19, 34-41.
160. van Aubel, R. A.; Smeets, P. H.; Peters, J. G.; Bindels, R. J.; Russel, F. G. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol., 2002, 13, 595-603.
161. Wielinga, P. R.; van der Heijden, I.; Reid, G.; Beijnen, J. H.; Wijnholds, J.; Borst, P. Characterization of the MRP4- and MRP5- mediated transport of cyclic nucleotides from intact cells. J. Biol. Chem., 2003, 278, 17664-17671.
162. Assaraf, Y. G.; Sierra, E. E.; Babani, S.; Goldman, I. D. Inhibitory effects of prostaglandin A1 on membrane transport of folates mediated by both the reduced folate carrier and ATP-driven exporters. Biochem. Pharmacol., 1999, 58, 1321-1327.
163. Zelcer, N.; Reid, G.; Wielinga, P.; Kuil, A.; van der Heijden, I.; Schuetz, J. D.; Borst, P. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem. J., 2003, 371, 361-367.
164. Leggas, M.; Adachi, M.; Scheffer, G. L.; Sun, D.; Wielinga, P.; Du, G.; Mercer, K. E.; Zhuang, Y.; Panetta, J. C.; Johnston, B.; Scheper, R. J.; Stewart, C. F.; Schuetz, J. D. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol. Cell. Biol., 2004, 24, 7612-7621.
165. Bai, J.; Lai, L.; Yeo, H. C.; Goh, B. C.; Tan, T. M. Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimaneglutathione. Int. J. Biochem. Cell. Biol., 2004, 36, 247-257.
166. Ito, K.; Suzuki, H.; Hirohashi, T.; Kume, K.; Shimizu, T.; Sugiyama, Y. Functional analysis of a canalicular multispecific organic anion transporter cloned from rat liver. J. Biol. Chem., 1998, 273, 1684-1688.
167. Hirohashi, T.; Suzuki, H.; Sugiyama, Y. Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J. Biol. Chem., 1999, 274, 15181-15185.
168. Belinsky, M. G.; Bain, L. J.; Balsara, B. B.; Testa, J. R.; Kruh, G. D. Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. J. Natl. Cancer Inst., 1998, 90, 1735-1741.
169. Rius, M.; Nies, A. T.; Hummel-Eisenbeiss, J.; Jedlitschky, G.; Keppler, D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology, 2003, 38, 374-384.
170. Madon, J.; Hagenbuch, B.; Landmann, L.; Meier, P. J.; Stieger, B. Transport function and hepatocellular localization of mrp6 in rat liver. Mol. Pharmacol., 2000, 57, 634-641.
171. Ilias, A.; Urban, Z.; Seidl, T. L.; Le Saux, O.; Sinko, E.; Boyd, C. D.; Sarkadi, B.; Varadi, A. Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6). J. Biol. Chem., 2002, 277, 16860-16867.
172. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2, 48-58.
173. Teodori, E.; Dei, S.; Martelli, C.; Scapecchi, S.; Gualtieri, F. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr. Drug Targets, 2006, 7, 893-909.
174. Perego, P.; De Cesare, M.; De Isabella, P.; Carenini, N.; Beggiolin, G.; Pezzoni, G.; Palumbo, M.; Tartaglia, L.; Pratesi, G.; Pisano, C.; Carminati, P.; Scheffer, G. L.; Zunino, F. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res., 2001, 61, 6034-6037.
175. Vail, D. M.; Amantea, M. A.; Colbern, G. T.; Martin, F. J.; Hilger, R. A.; Working, P. K. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin. Oncol., 2004, 31, 16-35.
176. Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov., 2006, 5, 219-234.
177. Schuetz, E. G.; Umbenhauer, D. R.; Yasuda, K.; Brimer, C.; Nguyen, L.; Relling, M. V.; Schuetz, J. D.; Schinkel, A. H. Altered expression of hepatic cytochromes P450 in mice deficient in one or more mdr1 genes. Mol. Pharmacol., 2000, 57, 188-197.
178. Nezasa, K.; Tian, X.; Zamek-Gliszczynski, M. J.; Patel, N. J.; Raub, T. J.; Brouwer, K. L. Altered hepatobiliary disposition of 5 (and 6)-carboxy-2',7'-dichlorofluorescein in ABCG2 (BCRP1) and ABCC2 (MRP2) knockout mice. Drug Metab. Dispos., 2006, 34, 718-723.
179. Chu, X. Y.; Strauss, J. R.; Mariano, M. A.; Li, J.; Newton, D. J.; Cai, X.; Wang, R. W.; Yabut, J.; Hartley, D. P.; Evans, D. C.; Evers, R. Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). J. Pharmacol. Exp. Ther., 2006, 317, 579-589.
180. Vlaming, M. L.; Mohrmann, K.; Wagenaar, E.; de Waart, D. R.; Elferink, R. P.; Lagas, J. S.; van Tellingen, O.; Vainchtein, L. D.; Rosing, H.; Beijnen, J. H.; Schellens, J. H.; Schinkel, A. H. Carcinogen and anticancer drug transport by MRP2 in vivo: studies using MRP2 (ABCC2) knockout mice. J. Pharmacol. Exp. Ther., 2006, 318, 319-327.
181. Manautou, J. E.; de Waart, D. R.; Kunne, C.; Zelcer, N.; Goedken, M.; Borst, P.; Elferink, R. O. Altered disposition of acetaminophen in mice with a disruption of the MRP3 gene. Hepatology, 2005, 42, 1091-1098.
182. Zehnpfennig, B.; Urbatsch, I. L.; Galla, H. J. Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry, 2009, 48, 4423-4430.
183. Hu, S.; Franke, R. M.; Filipski, K. K.; Hu, C.; Orwick, S. J.; de Bruijn, E. A.; Burger, H.; Baker, S. D.; Sparreboom, A. Interaction of imatinib with human organic ion carriers. Clin. Cancer Res., 2008, 14, 3141-3148.
184. Zhou, S. F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica, 2008, 38, 802-832.
185. Zhou, S. F.; Xue, C. C.; Yu, X. Q.; Li, C.; Wang, G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther. Drug Monit., 2007, 29, 687-710.
186. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science, 2009, 323, 1718-1722.
187. Beumer, J. H.; Buckle, T.; Ouwehand, M.; Franke, N. E.; LopezLazaro, L.; Schellens, J. H.; Beijnen, J. H.; van Tellingen, O. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Invest. New Drugs, 2007, 25, 1-7.
188. Ambudkar, S. V.; Kimchi-Sarfaty, C.; Sauna, Z. E.; Gottesman, M. M. P-glycoprotein: from genomics to mechanism. Oncogene, 2003, 22, 7468-7485.
189. Sarkadi, B.; Ozvegy-Laczka, C.; Nemet, K.; Varadi, A. ABCG2 a transporter for all seasons. FEBS Lett., 2004, 567, 116-120.